Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, according to a dual‑luciferase assay and western blot analysis, miRNA‑101‑3p was found to be a target of the lncRNA SNHG1 in OS, which further regulated the expression of Rho‑associated coiled‑coil‑containing protein kinase 1 (ROCK1).
|
30592267 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
AFAP1-AS1 is overexpressed in osteosarcoma and plays an oncogenic role in osteosarcoma through RhoC/ROCK1/p38MAPK/Twist1 signaling pathway, in which RhoC acts as the interaction target of AFAP1-AS1.
|
31443665 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Here, we examined the suppressive role of this miRNA and its target, <i>ROCK1,</i> in osteosarcoma (OS), a highly malignant bone tumor that mainly affects children and adolescents.
|
31136973 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Taken together, this study demonstrates that miR-144 inhibited tumor growth and metastasis in OS via dual-suppressing of RhoA and ROCK1, which could be a new therapeutic approach for the treatment of OS.
|
30674565 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Dysregulation of ROCK1 and ROCK2 was also described in OS, being associated to higher metastasis incidence and worse prognosis.
|
30864107 |
2019 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Previously, we reported that Rho associated coiled-coil containing protein kinase 1 (ROCK1), a metastatic-related gene was negatively regulated by microRNA-335-5p (miR-335-5p) and work as an oncogene in osteosarcoma.
|
29753317 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
SNHG5 acts as an oncogene in OS via the SNHG5-miR-26a-ROCK1 axis and is therefore a potential novel therapeutic target for OS treatment.
|
30114643 |
2018 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
The mRNA expression of ROCK1 in OS tissues was detected using RT‑qPCR analysis, and the biological roles of ROCK1 in OS cells were also evaluated.
|
29328417 |
2018 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to examine the role of miR-202-5p in the occurrence and formation of OS. miR-202-5p and Rho-associated coiled-coil containing protein kinase 1 (ROCK1) levels were assessed using RT-qPCR in OS tissues and cell lines.
|
29963151 |
2018 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Rho-associated coiled-coil kinase 1 (ROCK1) was then identified as a target of miR-148a in Saos-2 and U2OS cells, and the expression of ROCK1 was significantly increased in OS tissues and cell lines.
|
28117029 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Furthermore, miR-150 or ROCK1 may be potential therapeutic targets for the treatment of OS.
|
28454380 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
We showed that the expression of RhoA and its effector kinases ROCK1/2 was much higher in human osteosarcoma (OS) tissues and the human OS cell line U2OS than in nontumorous tissues and cell line hFOB 1.19 using western blot analysis and real-time PCR.
|
28225457 |
2017 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Long non-coding RNA HOXA11-AS functions as a competing endogenous RNA to regulate ROCK1 expression by sponging miR-124-3p in osteosarcoma.
|
28558357 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Moreover, knockdown of ROCK1 reversed the promotion effect of miR-101 knockdown on proliferation, migration, and invasion while promoted apoptosis of MG63 cells, suggesting that miR-101 acts as a tumor suppressor in osteosarcoma cells via targeting ROCK1.
|
28123850 |
2017 |
Osteosarcoma of bone
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Moreover, bioinformatics and luciferase reporter gene assays confirmed that miR-1908 targeted the mRNA 3'-UTR region of ROCK1, a characterized tumor promoter in OS.
|
28081735 |
2017 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In conclusion, the results of the present study suggested that miR‑144 acts as a tumor suppressor by targeting ROCK1 in osteosarcoma.
|
26081423 |
2015 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, miR-144 suppresses OS progression by directly downregulating ROCK1 and ROCK2 expression, and may be a promising therapeutic target for OS.
|
25912304 |
2015 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
In addition, the combined miR-340 downregulation and ROCK1 upregulation (miR-340-low/ROCK1-high) occurred more frequently in osteosarcoma tissues with positive metastasis (p < 0.001) and poor response to pre-operative chemotherapy (p = 0.002).
|
24398981 |
2014 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Collectively, these data indicate that miR-145 may act as a tumor suppressor and contributes to the progression of OS through targeting ROCK1.
|
24801908 |
2014 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, the expression of ROCK1 was significantly increased in the OS tissues and in the KHOS and U2OS cells.
|
24789502 |
2014 |
Osteosarcoma of bone
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, our findings suggest that miR-335 acts as tumor suppressor by targeting the ROCK1 gene and inhibiting osteosarcoma cells migration and invasion.
|
23975506 |
2013 |
Osteosarcoma of bone
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Finally, we established the relationship between expression levels of ROCK1 and clinical prognosis in osteosarcoma patients by using immunohistochemistry.
|
21387396 |
2011 |